Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹«¾È±¸¾È±¸ÇÔ¸ôÁõÈıº ȯÀÚ¿¡¼­ ÃÊÀ½ÆÄÀ¯µµÇÏ È÷¾Ë·ç·Ð»ê ÇÊ·¯ ÁÖÀÔ¼úÀÇ Ä¡·á È¿°ú Effect of Ultrasound-guided Hyaluronic Acid Filler Injection in Anophthalmic Enophthalmos Syndrome

´ëÇѾȰúÇÐȸÁö 2019³â 60±Ç 1È£ p.1 ~ 8
¹Ú³ëÇØ, ±èÅÂÈÆ, À±»ó¹®, ¾çÀç¿í,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú³ëÇØ ( Park No-Hae ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ»ê¹éº´¿ø ¾È°úÇб³½Ç

±èÅÂÈÆ ( Kim Tae-Hoon ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ»ê¹éº´¿ø ¾È°úÇб³½Ç
À±»ó¹® ( Youn Sang-Moon ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ»ê¹éº´¿ø ¾È°úÇб³½Ç
¾çÀç¿í ( Yang Jae-Wook ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ»ê¹éº´¿ø ¾È°úÇб³½Ç

Abstract

¸ñÀû: ¹«¾È±¸¾È±¸ÇÔ¸ôÁõÈıº ȯÀÚ¿¡¼­ ÃÊÀ½ÆÄÀ¯µµÇÏ È÷¾Ë·ç·Ð»ê ÇÊ·¯ ÁÖÀÔ¼úÀÇ Ä¡·á È¿°ú¿¡ ´ëÇØ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó°ú ¹æ¹ý: 2011³â 10¿ùºÎÅÍ 2017³â 9¿ù±îÁö ¹«¾È±¸¾È±¸ÇÔ¸ôÁõÈıºÀ¸·Î ÃÊÀ½ÆÄÀ¯µµÇÏ È÷¾Ë·ç·Ð»ê ÇÊ·¯ ÁÖÀÔ¼úÀ» ½ÃÇà ¹ÞÀº 14¸í(14¾È) À» ´ë»óÀ¸·Î ±× °á°ú¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ÁÖÀÔ¼úÀº ÃÊÀ½ÆÄÀ¯µµÇÏ¿¡ È÷¾Ë·ç·Ð»ê ÇÊ·¯¸¦ ±¸ÈÄ ¶Ç´Â ¾È°Ë¿¡ ÁÖÀÔÇÏ¿´´Ù. ¼ú ÈÄ 3°³¿ù°¿¡ ±íÀº À§´«²¨Ç®°í¶ûÀÇ È£Àü°ú ȯÀÚ ¸¸Á·µµ¿¡ ´ëÇÑ Æò°¡¸¦ ÇÏ¿´´Ù.

°á°ú: È÷¾Ë·ç·Ð»ê ÇÊ·¯´Â ´ë»óÀÚ´ç Æò±Õ 1.2 ¡¾ 0.4ȸÀÇ ÁÖÀÔ¼úÀÌ ½ÃÇàµÇ¾úÀ¸¸ç, ÁÖÀÔ¼ú´ç Æò±Õ 1.14 ¡¾ 0.30 mLÀÇ ÇÊ·¯¸¦ ÁÖÀÔÇÏ¿´´Ù. ÁÖÀÔ¼ú Àü ±íÀº À§´«²¨Ç®°í¶û ´Ü°è´Â Æò±Õ 3.06 ¡¾ 0.90Á¡À̾úÀ¸¸ç, ÁÖÀÔ¼ú ÈÄ Æò±Õ 0.20 ¡¾ 0.56Á¡À¸·Î À¯ÀÇÇÑ °¨¼Ò¸¦ º¸¿´´Ù. ȯÀÚÀÇ ¸¸Á·µµ´Â ÁÖÀÔ¼ú Àü ±íÀº À§´«²¨Ç®°í¶ûÀÌ ½ÉÇÒ¼ö·Ï, ÁÖÀÔ¼ú ÈÄ ±íÀº À§´«²¨Ç®°í¶ûÀÇ È£Àü Á¤µµ°¡ Ŭ¼ö·Ï ³ô¾Ò´Ù.

°á·Ð: ¹«¾È±¸¾È±¸ÇÔ¸ôÁõÈıº¿¡¼­ È÷¾Ë·ç·Ð»ê ÇÊ·¯ ÁÖÀÔ¼úÀº ¿Ü·¡¿¡¼­ ½±°Ô ½Ã¼úÀÌ °¡´ÉÇϸç, ºñ±³Àû ÀûÀº ºÎÀÛ¿ëÀ¸·Î ¿ì¼öÇÑ °á°ú¿Í ³ôÀº ¸¸Á·µµ¸¦ º¸¿©ÁÖ¾ú´Ù. ¶ÇÇÑ ¾È±¸ÇÔ¸ôÀÌ ½ÉÇÒ¼ö·Ï ÁÖÀÔ¼ú ÈÄ ¸¸Á·µµ°¡ ³ô¾Æ ¾È±¸ÇÔ¸ôÀÌ ½ÉÇÑ È¯ÀÚ¿¡¼­ ±³Á¤ ¹æ¹ýÀ¸·Î °í·ÁÇغ¼ ¼ö ÀÖÀ» °ÍÀÌ´Ù

Purpose: To evaluate the outcomes of ultrasound-guided hyaluronic acid filler injection in anophthalmic enophthalmos syndrome patients.

Methods: We retrospectively reviewed the clinical records of 14 patients who were diagnosed with anophthalmic enophthalmos syndrome and treated with ultrasound-guided hyaluronic acid filler injection from October 2011 to September 2017. Filler was injected transcutaneous in the retrobulbar area or eyelid under ultrasound guidance and improvement of superior deep sulcus and patient satisfaction after three months of injection were evaluated.

Results: The mean number of injections was 1.2 ¡¾ 0.4, and 1.14 ¡¾ 0.30 mL of hyaluronic acid filler was used for each injection. There was a significant decrease in mean superior deep sulcus grade from 3.06 ¡¾ 0.90 before injection to 0.20 ¡¾ 0.56 after injection. Patient satisfaction was higher in the severe superior deep sulcus before injection group who showed greater superior deep sulcus improvement.

Conclusions: Hyaluronic acid filler injections for patients with anophthalmic enophthalmos syndrome were easy to perform in the outpatient department and showed excellent outcomes. The more severe the enophthalmos, the higher the satisfaction after injection, which showed that hyaluronic acid filler injection was an effective treatment for patients with severe enophthalmos syndrome.

Å°¿öµå

Anophthalmos; Filler; Hyaluronic acid

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS